
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Department of Surgery, School of Medicine, Keio University, Tokyo 160-8582 [Y. I., T. K., Y. O., M. W., T. Te., K. K., M. K.]; and Cancer Research Laboratory, Taiho Pharmaceutical Co. Ltd., Saitama 357-8527 [T. Ta., H. O., M. F.], Japan
We investigated the correlation between tumor sensitivity to 5-fluorouracil (5-FU) and the enzymatic activity and mRNA levels of thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) using human tumor xenografts in nude mice. Three gastric carcinoma xenografts (SC-1-NU, St-4, and H-111), two colon carcinoma xenografts (Co-4 and Col-3-JCK), one pancreatic carcinoma xenograft (PAN-3-JCK), and one breast carcinoma xenograft (MX-1) were inoculated into nude mice. When the resultant tumors reached 100300 mg, 5-FU was administered i.p. at a dose of 60 mg/kg in a schedule of three times every 4 days, and the antitumor activity of 5-FU was evaluated as the relative mean tumor weight in treated mice compared to control mice. Xenografts were also inoculated into untreated nude mice. When tumors weighed 200300 mg, tumor tissues were resected for measurement of tumoral TS and DPD. TS and DPD activities were detected by the TS-binding assay and a radioenzymatic assay, respectively. mRNA levels were measured by semiquantitative reverse transcription-PCR, with glyceraldehyde-3-phosphate dehydrogenase coamplified as an internal standard. TS and DPD activities ranged from 84.7 to 775.5 fmol/mg protein and from not detectable to 79.7 pmol/min/mg protein, respectively. TS and DPD mRNA levels ranged from 0.51 to 9.90 and from not detectable to 0.93, respectively. The enzymatic activities of TS and DPD were correlated with observed mRNA levels. DPD levels were significantly correlated with 5-FU sensitivity, with high DPD activity and high DPD mRNA level resulting in low sensitivity to 5-FU. In contrast, no correlation between TS level and 5-FU sensitivity was observed. Tumoral DPD activity and DPD mRNA level may be useful indicators in predicting the antitumor activity of 5-FU.
This article has been cited by other articles:
![]() |
W. Ichikawa, H. Uetake, Y. Shirota, H. Yamada, N. Nishi, Z. Nihei, K. Sugihara, and R. Hirayama Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-based Chemotherapy for Metastatic Colorectal Cancer Clin. Cancer Res., February 1, 2003; 9(2): 786 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shirota, W. Ichikawa, H. Uetake, H. Yamada, Z. Nihei, and K. Sugihara Intratumoral Dihydropyrimidine Dehydrogenase Messenger RNA Level Reflects Tumor Progression in Human Colorectal Cancer Ann. Surg. Oncol., July 1, 2002; 9(6): 599 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tanaka-Nozaki, M. Onda, N. Tanaka, and S. Kato Variations in 5-Fluorouracil Concentrations of Colorectal Tissues as Compared with Dihydropyrimidine Dehydrogenase (DPD) Enzyme Activities and DPD Messenger RNA Levels Clin. Cancer Res., September 1, 2001; 7(9): 2783 - 2787. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. P. van Kuilenburg, E. W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, H. R. Waterham, F. Baas, D. J. Richel, and A. H. van Gennip Lethal Outcome of a Patient with a Complete Dihydropyrimidine Dehydrogenase (DPD) Deficiency after Administration of 5-Fluorouracil: Frequency of the Common IVS14+1G>A Mutation Causing DPD Deficiency Clin. Cancer Res., May 1, 2001; 7(5): 1149 - 1153. [Abstract] [Full Text] |
||||
![]() |
J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen Clin. Cancer Res., April 1, 2001; 7(4): 999 - 1009. [Abstract] [Full Text] |
||||
![]() |
R. Fujiwaki, K. Hata, K. Nakayama, M. Fukumoto, and K. Miyazaki Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3946 - 3951. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Grem, N. Harold, J. Shapiro, D.-Q. Bi, M. G. Quinn, S. Zentko, B. Keith, J. M. Hamilton, B. P. Monahan, S. Donavan, et al. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors J. Clin. Oncol., December 1, 2000; 18(23): 3952 - 3963. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel, L. Zoetekouw, H. Van Lenthe, R. A. De Abreu, J. G. Maring, P. Vreken, and A. H. van Gennip Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene Clin. Cancer Res., December 1, 2000; 6(12): 4705 - 4712. [Abstract] [Full Text] |
||||
![]() |
F. Tanaka, Y. Otake, T. Nakagawa, Y. Kawano, R. Miyahara, M. Li, K. Yanagihara, J. Nakayama, I. Fujimoto, K. Ikenaka, et al. Expression of Polysialic Acid and STX, a Human Polysialyltransferase, Is Correlated with Tumor Progression in Non-Small Cell Lung Cancer Cancer Res., June 1, 2000; 60(11): 3072 - 3080. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Uetake, W. Ichikawa, T. Takechi, M. Fukushima, Z. Nihei, and K. Sugihara Relationship between Intratumoral Dihydropyrimidine Dehydrogenase Activity and Gene Expression in Human Colorectal Cancer Clin. Cancer Res., October 1, 1999; 5(10): 2836 - 2839. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |